LUPIN.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 12:59):

Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs)...

Stats
Šios dienos apimtis	587 179
Vidutinė apimtis	1.20M
Rinkos kapitalizacija	736.47B
EPS	INR0 ( 2024-02-06 )
Kita pelno data	( INR11.24 ) 2024-05-06
Last Dividend	INR4.00 ( 2023-07-14 )
Next Dividend	INR0 ( N/A )
P/E	41.32
ATR14	INR0.956 (0.06%)

Tūris Koreliacija

Ilgas: 0.26 (neutral)

Trumpas: -0.82 (strong negative)

Signal:(51.076) Neutral

Lupin Limited Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Lupin Limited Koreliacija - Valiuta/Žaliavos

0.25
( neutral )

0.16
( neutral )

0.00
( neutral )

0.18
( neutral )

0.32
( neutral )

0.34
( neutral )

Lupin Limited Finansinės ataskaitos

Annual	2022
Pajamos:	INR162.70B
Bruto pelnas:	INR94.90B (58.33 %)
EPS:	INR9.46

FY	2022
Pajamos:	INR162.70B
Bruto pelnas:	INR94.90B (58.33 %)
EPS:	INR9.46

FY	2022
Pajamos:	INR161.93B
Bruto pelnas:	INR91.05B (56.23 %)
EPS:	INR-33.24

FY	2021
Pajamos:	INR149.29B
Bruto pelnas:	INR95.67B (64.08 %)
EPS:	INR26.84

Financial Reports:

No articles found.

Lupin Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR4.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR4.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Lupin Limited Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.31 - low (43.35%) | Divividend Growth Potential Score: 3.91 - Decrease likely (21.82%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.250	2002-01-24
Last Dividend	INR4.00	2023-07-14
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	24	--
Total Paid Out	INR80.35	--
Avg. Dividend % Per Year	0.37%	--
Score	2.12	--
Div. Sustainability Score	4.31
Div.Growth Potential Score	3.91
Div. Directional Score	4.11	--

Next Divdend (Est)
(2024-06-03)

INR3.85 Estimate 3.18 %

Dividend Stability

0.25 Very Poor

Dividend Score

2.12

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2002	INR0	0.00%
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR5.00	0.65%
2019	INR5.00	0.59%
2020	INR6.00	0.78%
2021	INR6.50	0.65%
2022	INR4.00	0.42%
2023	INR4.00	0.55%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SUPRIYA.NS	Dividend Junior	2023-09-15	Annually	3	0.10%
NCLIND.NS	Dividend Junior	2023-09-15	Semi-Annually	18	1.25%
ICEMAKE.NS	No Dividend Player	2023-09-14	Annually	7	0.81%
CDSL.NS	Dividend Junior	2023-08-25	Annually	7	0.92%
RPPL.NS	Dividend Junior	2023-08-24	Annually	6	0.31%
LIKHITHA.NS	Dividend Junior	2023-09-20	Annually	4	0.46%
GANESHHOUC.NS	Dividend Junior	2023-08-31	Sporadic	18	0.18%
APTUS.NS	Dividend Junior	2023-05-12	Semi-Annually	3	0.32%
TECHNOE.NS	Dividend Junior	2023-09-15	Annually	16	1.13%
ONGC.NS	Dividend Knight	2023-08-18	Semi-Annually	28	4.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0938	1.500	8.12	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.139	1.500	9.57	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	7.49	1.000	8.34	8.34	[3 - 30]
operatingCashFlowPerShareTTM	33.77	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	33.77	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.643	1.000	2.62	2.62	[0.2 - 0.8]
operatingProfitMarginTTM	0.131	1.000	9.39	9.39	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.31

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	41.08	1.000	5.95	0	[1 - 100]
returnOnEquityTTM	0.139	2.50	9.72	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	33.77	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.248	1.500	3.81	0	[0 - 0.4]
operatingCashFlowPerShareTTM	33.77	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.291	1.500	-1.393	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0806	1.000	-0.486	0	[0.1 - 0.5]
Total Score				3.91

Lupin Limited

Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). It offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastrointestinal, anti-infective, nonsteroidal anti-inflammatory drug therapy, respiratory, women's health, and anti-tuberculosis. The company is also involved in the provision of biosimilar and over-the-counter products; specialty products; and drug discovery and development programs in the therapeutic areas of oncology, immunology, and metabolic disorders, as well as bio clinical research activities. Lupin Limited network consists of 18 labs, 280 LupiMitra collection centers, and 450 pick-up points. It operates in India, the United States, the United Kingdom, South Africa, Australia, the Philippines, Germany, the Netherlands, Mexico, and Brazil. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.